©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessPrenatally abnormal corpus callosum, differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Prenatally abnormal corpus callosum contaiming 44 and altogether 117 curated genes according to the clinical signs

ID
PP0014
Number of genes
74 Accredited laboratory test
Examined sequence length
154,0 kb (Core-/Core-canditate-Genes)
259,0 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • Amniotic fluid (after amnocentesis)
  • Chorionic villus
  • Umbilical cord blood
Diagnostic indications

NGS +

[Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
AKT31440NM_005465.7AD
ANOS12043NM_000216.4XLR
ARID1A6858NM_006015.6AD
ARID1B6750NM_001374820.1AD
CCND2870NM_001759.4AD
CDON3795NM_016952.5AD
DCX1083NM_178153.3XL
DYNC1H113941NM_001376.5AD
EPG57740NM_020964.3AR
FOXG11470NM_005249.5AD
GLDC3063NM_000170.3AR
GLI24761NM_005270.5AD
HCCS807NM_005333.5XL
L1CAM3774NM_000425.5XLR
LRP213968NM_004525.3AR
MED126534NM_005120.3XLR
MID12004NM_000381.4XLR
NDE11008NM_001143979.2AR
PAFAH1B11233NM_000430.4AD
PAX61269NM_000280.5AD
PTCH14344NM_000264.5AD
RAB18621NM_021252.5AR
RAB3GAP12946NM_012233.3AR
RAB3GAP24182NM_012414.4AR
RELN10383NM_005045.4AR
SHH1389NM_000193.4AD
SIX3999NM_005413.4AD
SLC12A63453NM_133647.2AR
SMARCA24773NM_003070.5AD
SMARCA45040NM_001128849.3AD
SMARCB11158NM_003073.5AD
SMARCE11236NM_003079.5AD
SPG117332NM_025137.4AD
TBCD7465NM_005993.5AR
TGIF1819NM_173208.3AD
TUBA1A1356NM_006009.4AD
TUBA81350NM_018943.3AR
TUBB1335NM_178014.4AD
TUBB2A1338NM_001069.3AD
TUBB2B1338NM_178012.5AD
UPF3B1452NM_080632.3XLR
ZEB23645NM_014795.4AD
ZIC21599NM_007129.5AD
ARID25508NM_152641.4AD
B9D2528NM_030578.4AR
C12orf57381NM_138425.4AR
CDK5783NM_001164410.3AR
CDK5RAP25682NM_018249.6AR
CTNNA22583NM_001164883.2AR
DCC4344NM_005215.4AR
DHCR71428NM_001360.3AR
DISC12499NM_001012957.2AD
EOMES2118NM_001278182.2AR
FGFR22466NM_000141.5AD
FRMD4A4028NM_018027.5AR
GCSH522NM_004483.5AR
GLI34743NM_000168.6AD
KATNB11968NM_005886.3AR
KIF1A5073NM_004321.8AD, AR
KIF2A2235NM_001098511.3AD
KIF5C2874NM_004522.3AD
KIF74032NM_198525.3AR
LAMB15361NM_002291.3AR
MACF116293NM_012090.5AD
PAK31635NM_002578.5XLR
PDHB1080NM_000925.4AR
PTPN111782NM_002834.5AD
SZT210128NM_015284.4AR
TMTC32745NM_181783.4AR
TUBB31353NM_006086.4AD
TUBG11356NM_001070.5AD
VAX11005NM_001112704.2AR
YWHAE768NM_006761.5AD
ZNF4627716NM_021224.6AD

Informations about the disease

Clinical Comment

Abnormalities of the corpus callosum (ACC) are common malformations of the brain and usually diagnosed after the 20th week of gestation. Fetuses with isolated ACC have a better prognosis than those with additional abnormalities. Yet, the unpredictable neurodevelopmental outcomes of isolated ACC make prenatal counseling particularly challenging. ACC are heterogeneous disorders that can occur as manifestations in the context of >200 genetic syndromes and, in particular, are also observed in association with major malformations of the embryonic forebrain. The most common postnatal findings in patients with ACC include mental retardation, visual disturbances, speech delay, and seizures. Even in cases without developmental delay and normal intelligence, mild behavioral or social problems and ADHD have been described. Genetic factors are very common. Among genetic causes, a "syndromic diagnosis" is made in 30-45% of cases, and a monogenic cause can be identified in 20-35%. The numerous genetic causes of ACC are based on autosomal dominant, autosomal recessive, and X-linked inheritance. A negative molecular genetic result does not constitute exclusion of the clinical diagnosis.

Reference: https://www.sciencedirect.com/science/article/pii/B9780323371018000333?via%3Dihub

 

Synonyms
  • Agenesis of the corpus callosum with peripheral neuropathy (SLC12A6)
  • Allelic: Charcot-Marie-Tooth disease, axonal, type 2O (DYNC1H1)
  • Allelic: Charcot-Marie-Tooth disease, axonal, type 2X (SPG11)
  • Allelic: Metachondromatosis (PTPN11)
  • Allelic: Neuropathy, hereditary sensory, type IIC (KIF1A)
  • Allelic: Rigidity + multifocal seizure syndrome, lethal neonatal (BRAT1)
  • Allelic: Spastic paraplegia 30, AD (KIF1A)
  • Allelic: Spastic paraplegia 30, AR (KIF1A)
  • Allelic: Spinal muscular atrophy, lower extremity-predominant 1, AD (DYNC1H1)
  • Amyotrophic lateral sclerosis 5, juvenile (SPG11)
  • Aniridia (PAX6)
  • Anterior segment dysgenesis 5, multiple subtypes (PAX6)
  • Aqueductal stenosis [panelapp] (SMARCC1)
  • Bainbridge-Ropers syndrome (ASXL3)
  • Basal cell nevus syndrome (PTCH1)
  • Blepharophimosis-impaired intellectual development syndrome (SMARCA2)
  • CRASH syndrome (L1CAM)
  • Cataract with late-onset corneal dystrophy (PAX6)
  • Coffin-Siris syndrome 1 (ARID1B)
  • Coffin-Siris syndrome 2 (ARID1A)
  • Coffin-Siris syndrome 3 (SMARCB1)
  • Coffin-Siris syndrome 4 (SMARCA4)
  • Coffin-Siris syndrome 5 (SMARCE1)
  • Coloboma of optic nerve (PAX6)
  • Coloboma, ocular (PAX6)
  • Congenital hydrocephalus [panelapp] (SMARCC1)
  • Corpus callosum abnormalities [panelapp] (SMARCC1)
  • Corpus callosum, agenesis of, with facial anomalies, cerebellar ataxia (FRMD4A)
  • Corpus callosum, partial agenesis of (L1CAM)
  • Cortical dysplasia, complex, with other brain malformations 5 (TUBB2A)
  • Cortical dysplasia, complex, with other brain malformations 6 ITUBB)
  • Cortical dysplasia, complex, with other brain malformations 7 (TUBB2B)
  • Culler-Jones syndrome (GLI2)
  • Developmental + epileptic encephalopathy 1 (ARX)
  • Donnai-Barrow syndrome (LRP2)
  • Encephalopathy, progressive, early-onset, brain atrophy, thin corpus callosum (TBCD)
  • Epilepsy, familial temporal lobe, 7 (RELN)
  • Foveal hypoplasia 1 (PAX6)
  • Glycine encephalopathy (GLDC)
  • Hardikar syndrome (MED12)
  • Holoprosencephaly 11 (CDON)
  • Holoprosencephaly 2 (SIX3)
  • Holoprosencephaly 3 (SHH)
  • Holoprosencephaly 4 (TGIF1)
  • Holoprosencephaly 5 (ZIC2)
  • Holoprosencephaly 7 (PTCH1)
  • Holoprosencephaly 9 (GLI2)
  • Hydranencephaly with abnormal genitalia (ARX)
  • Hydrocephalus due to aqueductal stenosis (L1CAM)
  • Hydrocephalus with Hirschsprung disease (L1CAM)
  • Hydrocephalus with congenital idiopathic intestinal pseudoobstruction (L1CAM)
  • Hypogonadotropic hypogonadism 1 with/-out anosmia, Kallmann syndrome 1 (ANOS1)
  • Intellectual developmental disorder with dysmorphic facies + ptosis (BRPF1)
  • Intellectual developmental disorder, AD 13 (DYNC1H1)
  • Intellectual developmental disorder, AD 36 (PPPR1A)
  • Intellectual developmental disorder, XL 29 (ARX)
  • Intellectual developmental disorder, XL syndromic 14 (UPFB)
  • Intellectual developmental disorder, XL syndromic, Stocco dos Santos type (SHROOM4)
  • Keratitis (PAX6)
  • Koolen-De Vries syndrome (KANSL1)
  • LEOPARD syndrome 1 (PTPN11)
  • Linear skin defects with multiple congenital anomalies 1 (HCCS)
  • Lissencephaly 1 (PAFAH1B1)
  • Lissencephaly 2, Norman-Roberts type (RELN)
  • Lissencephaly 3 (TUBA1A)
  • Lissencephaly 4, with microcephaly (NDE1)
  • Lissencephaly, XL (DCX)
  • Lissencephaly, XL 2 (ARX)
  • Lujan-Fryns syndrome (MED12)
  • MASA syndrome (L1CAM)
  • Macrothrombocytopenia, isolated, 2, AD (TUBA8)
  • Martsolf syndrome 1 (RAB3GAP2)
  • Martsolf syndrome 2 (RAB3GAP1)
  • Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 (AKT3)
  • Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (CCND2)
  • Meningioma, familial, susceptibility to (SMARCE1)
  • Microcephaly, short stature + polymicrogyria with seizures (RTTN)
  • Microhydranencephaly (NDE1)
  • Microphthalmia with coloboma 5 (SHH)
  • Morning glory disc anomaly (PAX6)
  • Mowat-Wilson syndrome (ZEB2)
  • NESCAV syndrome (KIF1A)
  • Neurodevelopmental disorder with cerebellar atrophy with/-out seizures (BRAT1)
  • Nicolaides-Baraitser syndrome (SMARCA2)
  • Noonan syndrome 1 (PTPN11)
  • Ohdo syndrome, XL (MED12)
  • Opitz GBBB syndrome (MID1)
  • Opitz-Kaveggia syndrome (MED12)
  • Optic nerve hypoplasia (PAX6)
  • Partington syndrome (ARX)
  • Prenatally unusual structure of the corpus callosum
  • Primrose syndrome (ZBTB20)
  • Proud syndrome (ARX)
  • Rett syndrome, congenital variant (FOXG1)
  • Rhabdoid tumor predisposition syndrome 1 (SMARCB1)
  • Rhabdoid tumor predisposition syndrome 2 (SMARCA4)
  • Schizencephaly (SHH)
  • Schizencephaly (SIX3)
  • Schwannomatosis-1, susceptibility to (SMARCB1)
  • Septal agenesis [panelapp] (SMARCC1)
  • Single median maxillary central incisor (SHH)
  • Spastic paraplegia 11, AR (SPG11)
  • Subcortical laminal heterotopia, XL (DCX)
  • Subcortical laminar heterotopia (PAFAH1B1)
  • Symmetric circumferential skin creases, congenital, 1 ITUBB)
  • Vici syndrome (EPG5)
  • Warburg micro syndrome 1 (RAB3GAP1)
  • Warburg micro syndrome 2 (RAB3GAP2)
  • Warburg micro syndrome 3 (RAB18)
  • Weiss-Kruszka syndrome (ZNF462)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.